How it went
Did it last?
- No one said the benefit wore off.
- No one said they needed to keep it up to stay well.
Read from what people wrote. A story that ends without a follow-up counts as lasting, so treat these as minimums.
| Outcome described | Accounts | Share |
|---|---|---|
| Full recovery | 1 | 33% |
| Near-full | 0 | 0% |
| Substantial | 1 | 33% |
| Partial | 1 | 33% |
| Relapsed | 0 | 0% |
| No benefit | 0 | 0% |
Only 3 accounts. Treat these percentages as anecdotes, not rates.
By how ill people were
| Severity at worst | How it went | n | Recovered |
|---|---|---|---|
| Very severe | 1 | 0% |
2 accounts don’t say how ill the person was.
Who published these accounts
33% of these accounts are on pages that sell this treatment or a program around it. Those pages publish their successes; compare the independent row.
All 3 accounts
-
Experimental peptides are being advertised for Long COVID (Joshua)
Joshua began microdosing tirzepatide about six months before the article was written, though no specific dose is given. The article does not describe how long he had been sick or how severe his Long COVID was, but he reported that within hours of his first…
-
ME/CFS patient substantially improved with spironolactone 100 mg daily
Poster combined spironolactone 25mg/day with LDN, a GLP-1 agonist and NP thyroid and states plainly "My CFS is cured, yes cured...my health is amazing," while noting he still needs cortisol supplementation. Because several drugs were changed together it is…
-
Scripps launches digital clinical trial to test repurposed drug for Long COVID
Credits GLP 1. An unnamed patient was ill 1y with very-severe long COVID and reports a substantial improvement. Poster's daughter, bedridden a year, thriving days after Ozempic.